申请人:——
公开号:US20030013707A1
公开(公告)日:2003-01-16
The use of a compound comprising formula (I):
1
(I)
or a salt, ester, amide or prodrug therof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them.
In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and
R
1
is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.
使用化合物公式(I):1(I)或其盐、酯、酰胺或前药来抑制一种首选作用方式为催化酯官能团水解的酶的活性,例如在产品和过程中控制和抑制不需要的酶。该化合物在医学上也有用,例如在肥胖和相关疾病的治疗中。该发明还涉及公式(I)中的新化合物,制备它们的方法以及含有它们的药物组合物。在公式(I)中,A是6元芳香或杂芳香环;R1是支链或直链烷基(可以被一个或多个氧原子中断)、烯基、炔基、环烷基、环烯基、芳基、芳基烷基、还原芳基烷基、芳基烯基、杂芳基、杂芳基烷基、还原芳基、还原杂芳基烷基或任何上述基团的取代衍生物。